Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lesion network localization of depression in multiple sclerosis.

Nature. Mental health·2026
Same author

Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults.

Nature communications·2026
Same author

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.

Blood advances·2026
Same author

Assessment of the impact of outcome definitions on power in multiple sclerosis clinical trials.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2026

Related Experiment Video

Updated: Jun 3, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Patient reported outcomes in benign multiple sclerosis.

Line E Hviid1, Brian C Healy, David J Rintell

  • 1Partners Multiple Sclerosis Center, Brigham and Women's Hospital/Harvard Medical Institute, Brookline, MA 02445, USA. hviid@partners.org

Multiple Sclerosis (Houndmills, Basingstoke, England)
|March 5, 2011
PubMed
Summary
This summary is machine-generated.

Patients with benign multiple sclerosis (MS) report better outcomes than those with more severe MS. However, patient-reported outcomes differ based on how benign MS is defined, highlighting the impact of disease duration and disability.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neurology
  • Clinical Research
  • Patient-Reported Outcomes

Background:

  • Benign multiple sclerosis (MS) is characterized by a mild disease course with minimal disability accumulation.
  • Patient-reported outcomes (PROs) in benign MS are not well understood.

Purpose of the Study:

  • To compare PROs in benign MS patients against those with similar disease duration or disability.
  • To investigate the impact of defining benign MS on PROs.

Main Methods:

  • Two benign MS cohorts (EDSS ≤1.5 or ≤3.0) were compared with other MS groups based on disease duration and EDSS.
  • PROs assessed included quality of life (QOL), fatigue, depression, social support, and cognitive function.

Main Results:

  • Benign MS groups reported better PROs than Late MS patients (EDSS >3.0).
  • Significant differences in QOL, depression, and fatigue were observed between Benign-1.5 and Early-MS groups.
  • Benign-3 patients showed worse depression and cognition compared to specific control groups.

Conclusions:

  • Benign MS patients generally exhibit superior PROs compared to other MS patient groups.
  • Both disease duration and disability level significantly influence PROs in MS.
  • The definition of benign MS impacts observed PROs, underscoring the importance of precise classification.